KTTA Pasithea Therapeutics Corp.
Stock Price & Overview

$2.65-0.02 (-0.75%)3:59 PM 12/13/24
NASDAQ | $USD | Post-Market: $2.60 -0.05 (-1.89%) 5:16 PM

KTTA Stock Price

EPS
PE
Div Rate
Yield
Short Interest
Market Cap
Volume
Prev. Close
Expand For Key Data »

Quant Ranking

KTTA Analysis

KTTA News

See All News »

Latest Headlines

People Also Follow

Similar to KTTA

ETFs Holding KTTA

KTTA Company Profile

Pasithea Therapeutics Corp. logo
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Sector
Health Care
Industry
Biotechnology
Employees
8
Founded
2020
Address
  • 1111 Lincoln Road
  • Suite 500
  • Miami Beach, FL, 33139
  • United States
Phone Number
702 514 4174
Website
www.pasithea.com
Hide

KTTA Revenue

More On Revenue »

KTTA Earnings Per Share

More On Earnings »

Earnings Revisions

Valuation

Profitability

Momentum

Capital Structure

Dividends

KTTA does not currently pay a dividend.

KTTA Ownership

KTTA Peers

Risk

Technicals

KTTA SEC Filings

See All SEC Filings »

Press Releases

See All Press Releases »

KTTA Income Statement

KTTA Balance Sheet

KTTA Cash Flow Statement

KTTA Long Term Solvency

Discover More

You may be interested in:

Pasithea Therapeutics Corp. (KTTA) Frequently Asked Questions